A study on CYP2C9 polymorphism in Puerto Rican Alzheimer's Patients and its role in the Pharmacokinetics of ∆-9-tetrahydrocanna-binol

Main Article Content

Jagadeesh S Rao William Julio Varduhi Ghazaryan Evelyn Gutiérrez Claudia Grimaldi Saadia S Shahnawaz Laura Sánchez Maria Alejandra Tangarife María Juanita Arbeláez María Margarita Venegas Laura Delgado- Murillo Ram Mukunda

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disease that affects over 55 million people worldwide. Individuals with AD are often prescribed multiple medications to manage comorbidities, many of which are metabolized by enzymes from the cytochrome P450 (CYP). CYP2C9 is expressed by the CYP2C9 gene. The highly polymorphic gene is grouped into phenotypes such as poor, intermediate, normal, and ultra-rapid metabolizers that influence the pharmacokinetics (PK) of drugs and their metabolites. Among humans, CYP2C9 is one of the most essential enzymes for metabolizing drugs, including delta-9-tetrahydrocannabinol (THC). The enzyme converts THC into its active metabolite 11-hydroxy-delta-9-THC (OH-THC). IGC-AD1 is a formulation with two active pharmaceutical ingredients, delta-9-THC and melatonin. The Phase 1, multiple ascending dose (MAD) trial, was conducted on a Puerto Rican population. The participant population in the trial (N=13) was 69.2% female and 30.8% male, with an average age of 80.18 (SD+/- 6.22). We report on the effect of CYP2C9 polymorphisms on the pharmacokinetics (PK) of THC and its active metabolite in AD patients from a Phase 1 trial. Using a Mass ARRAY Analyzer 4 Instrument (Invitae Inc.), we determined the following CYP2C9 alleles: *2, *3, *4, *5, *6, *8, *11, *13, *15, and found that 60% of participants (N=6) were carriers of at least one polymorphism including 1*/2* and 1*/3*. The participants with intermediate metabolizers (*1/*3 and *1/*2) showed an increased half-life of THC and OH-THC with major differences between the two intermediate metabolizer groups *1/*3 and *1/*2. In the trial more females were noted to be intermediate metabolizers than males. As polymorphisms of CYP2C9 affect the PK of THC and its metabolite, larger studies are needed to establish PK baselines for polymorphisms of CYP2C9. In the meantime, it is recommended that researchers exercise caution while dosing AD patients with THC.

Keywords: Alzheimer’s disease, Genotyping, CYP2C9, THC, Pharmacokinetics, Intermediate metabolizer, Latino population

Article Details

How to Cite
RAO, Jagadeesh S et al. A study on CYP2C9 polymorphism in Puerto Rican Alzheimer's Patients and its role in the Pharmacokinetics of ∆-9-tetrahydrocanna-binol. Medical Research Archives, [S.l.], v. 12, n. 4, may 2024. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/5380>. Date accessed: 19 july 2024. doi: https://doi.org/10.18103/mra.v12i4.5380.
Section
Research Articles

References

1. Kantayeva G, Lima J, Pereira AI. Application of machine learning in dementia diagnosis: A systematic literature review. Heliyon. Nov 2023;9(11)e21626.
2. Alzheimer’s Association. Alzheimer’s Disease Facts and Figures. . Alzheimers Dement. 2024 20 ( 5 ).
3. Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol. 2012;(3)(73)(1-21).
4. Formiga F, Fort I, Robles MJ, et al. Comorbidity and clinical features in elderly patients with dementia: differences according to dementia severity. J Nutr Health Aging. May 2009;13(5)423-7.
5. Guo J, Gao B, Huang Y, Song S. Trajectory of multimorbidity before dementia: A 24-year follow-up study. Alzheimers Dement (Amst). Jan-Mar 2024;16(1)e12523.
6. Forgerini M, Herdeiro MT, Galduroz JCF, Mastroianni PC. Risk factors associated with drug therapy among elderly people with Alzheimer's disease: a cross-sectional study. Sao Paulo Med J. Jun 2020;138(3)216-218.
7. Ingelman-Sundberg M. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol. Jan 2004;369(1)89-104.
8. Zahoor I, Rui B, Khan J, Datta I, Giri S. An emerging potential of metabolomics in multiple sclerosis: a comprehensive overview. Cell Mol Life Sci. Apr 2021;78(7)3181-3203.
9. Lin JH, Lu AY. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol. 2001;41535-67.
10. Sadee W, Wang D, Papp AC, et al. Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy. Clin Pharmacol Ther. Mar 2011;89(3)355-65.
11. Riaz S, Muhammad Din S, Usman Tareen M, et al. Genetic Polymorphism of CYP2C19 in Pakistani Population. Iran J Pharm Res. Spring 2019;18(2)1097-1102.
12. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome P450 "pie". Drug Metab Dispos. May 2006;34(5)880-6.
13. Isvoran A, Louet M, Vladoiu DL, et al. Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism. Drug Discov Today. Feb 2017;22(2)366-376.
14. Daly AK, Rettie AE, Fowler DM, Miners JO. Pharmacogenomics of CYP2C9: Functional and Clinical Considerations. J Pers Med. Dec 28 2017;8(1)
15. Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. Aug 2020;108(2)191-200.
16. Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. Sep 2017;102(3)397-404.
17. Lemberger L, Silberstein SD, Axelrod J, Kopin IJ. Marihuana: studies on the disposition and metabolism of delta-9-tetrahydrocannabinol in man. Science. Dec 18 1970;170(3964)1320-2.
18. Babayeva M, Loewy ZG. Cannabis Pharmacogenomics: A Path to Personalized Medicine. Curr Issues Mol Biol. Apr 17 2023;45(4)3479-3514.
19. Bornheim LM, Lasker JM, Raucy JL. Human hepatic microsomal metabolism of delta 1-tetrahydrocannabinol. Drug Metab Dispos. Mar-Apr 1992;20(2)241-6.
20. Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci. Mar 20 2007;80(15)1415-9.
21. Ma X, Idle JR, Krausz KW, Gonzalez FJ. Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. Apr 2005;33(4)489-94.
22. Claudio-Campos K, Monero-Paredes M, Hernandez E, Renta J, Duconge J. Low-frequency variants at the CYP2C9 locus among Puerto Rican patients on warfarin: in silico predictions of functionality and conservation. Pharmacogenomics. Aug 2019;20(12)891-902.
23. Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev. Sep 2006;58(3)(521-90.
24. Kim K, Johnson JA, Derendorf H. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol. Oct 2004;44(10)1083-105.
25. Rettie AE, Haining RL, Bajpai M, Levy RH. A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res. Jul 1999;35(3)253-5.
26. Niinuma Y, Saito T, Takahashi M, et al. Functional characterization of 32 CYP2C9 allelic variants. Pharmacogenomics J. Apr 2014;14(2)107-14.
27. Hirota T, Eguchi S, Ieiri I. Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs. Drug Metab Pharmacokinet. 2013;28(1)28-37.
28. Sachse-Seeboth C, Pfeil J, Sehrt D, et al. Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. Clin Pharmacol Ther. Mar 2009;85(3)273-6.
29. Wiley JL, Burston JJ. Sex differences in Delta(9)-tetrahydrocannabinol metabolism and in vivo pharmacology following acute and repeated dosing in adolescent rats. Neurosci Lett. Jul 25 2014;57651-5.
30. Sallam NA, Peterson CS, Baglot SL, et al. Sex Differences in Plasma, Adipose Tissue, and Central Accumulation of Cannabinoids, and Behavioral Effects of Oral Cannabis Consumption in Male and Female C57BL/6 Mice. Int J Neuropsychopharmacol. Nov 24 2023;26(11)773-783.
31. Lunn S, Diaz P, O'Hearn S, et al. Human Pharmacokinetic Parameters of Orally Administered Delta(9)-Tetrahydrocannabinol Capsules Are Altered by Fed Versus Fasted Conditions and Sex Differences. Cannabis Cannabinoid Res. 2019;4(4)255-264.
32. Baglot SL, Hume C, Petrie GN, et al. Pharmacokinetics and central accumulation of delta-9-tetrahydrocannabinol (THC) and its bioactive metabolites are influenced by route of administration and sex in rats. Sci Rep. Dec 14 2021;11(1)23990.
33. Papastergiou J, Li W, Sterling C, van den Bemt B. Pharmacogenetic-guided cannabis usage in the community pharmacy: evaluation of a pilot program. J Cannabis Res. Sep 1 2020;2(1)24.